Lorundrostat Shows Promise in Treating Resistant Hypertension
A new phase 2b study has found that lorundrostat, an investigational aldosterone synthase inhibitor, effectively lowers blood pressure for adults with resistant hypertension. The study, known as ADVANCE-HTN, involved 285 participants who were randomly assigned to receive either 50mg of lorundrostat daily or placebo for 12 weeks. The results showed that the lorundrostat group had … Read more